polycythemia vera
Infectious disease · 2017–2019
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ruxolitinib Treatment of polycythemia vera in patients who are resistant or intolerant to hydroxycarbamide/hydroxyurea. | Nov 2019 | Not recommended | 7 individuals Leukaemia Foundation |
| peginterferon alfa-2a Chronic hepatitis B and C infection, with potential off-label use in myeloproliferative neoplasms (MPN) including essential thrombocythemia and polycythemia… | Nov 2017 | Recommended with restriction | 4 individuals Rare Cancers Australia |
Who spoke
Rare Cancers Australia · Leukaemia Foundation
What the PBS pays
$124M in government benefit over 2024–25, across 44,864 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ruxolitinib | $113.4M |
| peginterferon alfa-2a | $11M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.